Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
When measured before chemotherapy, along with age, the level of a hormone released in young women’s ovaries may predict whether the ovaries will work again after chemotherapy.
Researchers found that among women with breast cancer living in rural areas, those who believe in their ability to exercise, believe there are few roadblocks preventing them from exercising, and have low levels of fatigue are most likely to get the recommended amount of exercise.
Researchers with the Southwest Oncology Group (SWOG) S0221 clinical trial gave similar chemotherapy treatments to people with high-risk, early-stage breast cancer. But they assigned some people to daily and weekly treatment, and others to treatment once every 2 weeks, or biweekly. They found that, overall, no treatment schedule stopped cancer from returning better than the other. However, a sub-analysis suggested people with triple-negative breast cancer did better with a biweekly schedule than with a daily and weekly schedule.
Pfizer, a company that makes and sells medicine, announced Feb. 3 that the U.S. Food and Drug Administration (FDA) granted accelerated approval of its anticancer medicine, palbociclib (Ibrance) – in combination with letrozole (Femara) – for postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer.
A recent study examined the average number of repeat surgeries needed for women undergoing lumpectomy, also calledbreast conservation surgery. The study found that approximately one-fourth of women who have breast conservation surgery go on to have some type of repeat breast surgery – whether an additional lumpectomy or complete mastectomy.
A study found that women taking low-cost, generic aromatase inhibitors were more likely to stick to their treatment plans than women who took more expensive, brand-name medicines. More than half of the women in this study stopped buying their aromatase inhibitors early or took them less often than recommended.
MARIANNE Trial Shows T-DM1 Works About As Well As Standard First Treatment for HER2-Positive Metastatic Breast Cancer
At the end of 2014, the pharmaceutical company Genentech announced results from the phase III MARIANNE trial. These results show that T-DM1, with or without pertuzumab, works about as well as, but not significantly better than, the standard treatment for people newly diagnosed with HER2-positive metastatic breast cancer. Both T-DM1 and pertuzumab are sold by Genentech. The final results of MARIANNE will be presented at a future medical meeting and are not yet published in a medical journal.
Despite the importance for free clinics to promote breast health education to populations of women who may not get routine screenings or schedule regular check-ups, a recent study conducted at one such free clinic in the Intermountain West found that breast health information was limited. This was especially true among Spanish speakers and non-U.S. citizen English speakers.
The largest study of long-term breast cancer treatment using methods to stop estrogen production in premenopausal women with hormone receptor-positive disease has found what one of its authors calls “practice-changing” results for certain women.
Researchers found that immediate breast reconstruction, surgery to rebuild the breast done at the same time as mastectomy, is most likely to be used by young women in big cities who have private insurance and few chronic medical problems. Overall though, more women do NOT have their breasts rebuilt at that time.